Written by : Saloni Tyagi
May 1, 2025
This collaboration aims to improve timely access to critical blood products while enhancing operational efficiency across the healthcare sector.
Lytus Technologies has announced the completion of its acquisition of Blod.in, an AI and ML-powered on-demand platform for blood component management and logistics.
This collaboration aims to improve timely access to critical blood products while enhancing operational efficiency across the healthcare sector.
As part of its broader growth strategy, Lytus Technologies has committed INR 1,000 Cr in capital over the next three years to scale both organically and inorganically, expand its digital ecosystem, and accelerate HealthTech innovation.
Dharmesh Pandya, CEO of Lytus Technologies, said, “At Lytus HealthTech, we are committed to building scalable solutions that seamlessly integrate Advanced AI, ML, and Agentic AI to transform the future of blood and medical logistics. Our focus is on improving access, streamlining workflows, and delivering better patient outcomes across India.”
A key portion of this investment will go toward AI and ML-powered solutions under Lytus Healthtech, including enhancements to Blod.in’s proprietary AI engine.
This engine supports functions such as predictive inventory management, real-time supply-demand analytics, and last-mile routing for temperature-sensitive deliveries.
“Our AI-first model enables proactive collaboration, not reactive firefighting ensuring every patient, every hospital, and every unit of blood is accounted for with precision and care,” Sai Guna Ranjan Puranam, COO, Lytus HealthTech, added,
Over the past year, Blod.in has rapidly scaled from partnering with 30 to 140 hospitals, maintaining a 20% month-on-month growth rate.
With operations established in Chennai, the platform is targeting expansion to an additional 100 hospitals and over 15 blood banks. Further geographic growth is planned in Bengaluru, Mumbai, Hyderabad, and other major cities.
Blod.in’s AI-driven logistics model is also set to enter international markets such as the US and UAE, focused on optimising inventory, reducing wastage, and ensuring timely blood access for patients, hospitals, and blood banks.